#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2568	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2402	316.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1598	1598	C	398	C	345	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2568	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2402	316.0	0	HET	.	.	.	A37T	.	37	37	A	451	451	A	343	A,T	237,73	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4086	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4043	302.4	0	.	n	.	0	T695C	SNP	695	695	T	1327	1327	C	304	C,T,A	251,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4086	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4043	302.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1969	1969	A	402	A	328	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4086	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4043	302.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2603	2603	C	341	C,T	291,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4086	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4043	302.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3229	3229	T	340	T,C	164,133	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	4086	23S	2890	2890	99.86	23S.l6.c4.ctg.1	4043	302.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2677	2677	A	363	A	305	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	410	folP	852	852	100.0	folP.l6.c4.ctg.1	1915	64.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1213	1215	AGC	90;90;90	A;G;C,A	73;75;76,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	900	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3753	71.7	1	SNP	p	S91F	0	.	.	271	273	TCC	806	808	TCC	85;84;85	T;C;C	71;73;75	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	900	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3753	71.7	1	SNP	p	D95N	0	.	.	283	285	GAC	818	820	GAC	84;84;84	G,C;A;C	74,1;74;72	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	900	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3753	71.7	1	SNP	p	D95G	0	.	.	283	285	GAC	818	820	GAC	84;84;84	G,C;A;C	74,1;74;72	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	346	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1709	60.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	616	618	ACC	108;108;106	A;C;C	85;87;87	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	346	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1709	60.4	0	.	p	.	0	R44H	NONSYN	130	132	CGC	631	633	CAC	102;103;103	C;A;C	82;83;84	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	346	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1709	60.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	814	816	CAC	99;98;97	C;A;C	89;88;89	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	346	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1709	60.4	1	SNP	p	G45D	0	.	.	133	135	GGC	634	636	GGC	104;104;104	G;G,C;C	85;83,1;87	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	252	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1301	57.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3264	85.3	1	SNP	p	D86N	0	.	.	256	258	GAC	705	707	GAC	120;119;119	G;A,G;C	98;93,1;97	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3264	85.3	1	SNP	p	S87I	0	.	.	259	261	AGT	708	710	AGT	118;119;119	A;G;T	92;100;96	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3264	85.3	1	SNP	p	S87R	0	.	.	259	261	AGT	708	710	AGT	118;119;119	A;G;T	92;100;96	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3264	85.3	1	SNP	p	S87W	0	.	.	259	261	AGT	708	710	AGT	118;119;119	A;G;T	92;100;96	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	932	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3264	85.3	1	SNP	p	S88P	0	.	.	262	264	TCC	711	713	TCC	119;119;118	T;C,A;C	99;96,1;97	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	742	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3001	74.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1759	1761	GGC	85;86;86	G,A,T;G,A;C	72,1,1;71,1;73	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1401	1403	GCA	99;98;99	G,T;C;A	81,1;80;83	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1404	1406	ATC	99;99;99	A;T;C	86;82;86	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1416	1418	GTG	99;99;100	G;T;G	83;84;83	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1416	1418	GTG	99;99;100	G;T;G	83;84;83	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1920	1922	ACC	78;78;78	A;C;C	67;66;70	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1974	1976	GCG	77;76;75	G;C,G;G	61;58,1;60	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1974	1976	GCG	77;76;75	G;C,G;G	61;58,1;60	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2097	2099	GGC	65;65;65	G;G;C	55;52;55	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2106	2108	GGC	64;64;63	G;G;C	55;54;52	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	676	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2766	72.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2124	2126	CCG	63;64;64	C,T;C;G	51,1;55;52	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	818	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3556	68.8	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1831	1833	CTG	88;88;89	C;T;G	65;67;69	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	514	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2302	66.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	755	755	C	92	C	78	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	D41K	NONSYN	121	123	GAC	598	600	AAA	93;93;94	A,G;A;A,C	76,1;78;79,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	A109V	NONSYN	325	327	GCC	802	804	GTC	98;99;100	G;T;C	83;82;84	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	868	870	TAT	99;99;98	T;A;T	80;86;76	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	N134E	NONSYN	400	402	AAT	877	879	GAG	95;95;96	G;A;G	78;81;80	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	V135L	NONSYN	403	405	GTG	880	882	CTT	96;96;97	C;T;T	80;82;81	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	G140K	NONSYN	418	420	GGA	895	897	AAA	98;99;98	A;A;A	82;84;85	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	K143G	NONSYN	427	429	AAA	904	906	GGA	93;94;93	G;G;A	82;79;81	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	928	930	GCA	95;96;95	G;C;A	80;79;78	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	D171G	NONSYN	511	513	GAC	988	990	GGT	98;98;97	G;G;T	86;83;81	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1036	1038	CGA	106;106;106	C;G;A	88;89;85	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	Y211_E212insL	INS	631	631	T	1108	1108	T	95	T	79	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1114	1116	GAT	95;94;95	G;A;T	77;77;80	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	H213D	NONSYN	637	639	CAT	1117	1119	GAT	95;94;94	G;A;T	79;80;80	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	464	porB1b	1047	1047	96.01	porB1b.l15.c4.ctg.1	1835	74.4	0	.	p	.	0	Q214fs	FSHIFT	640	640	C	1120	1120	C	93	C	78	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1716	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5453	94.2	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2267	2269	AAT	98;98;98	A;A;T	82;80;85	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	258	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1320	58.5	1	SNP	p	V57M	1	.	.	169	171	ATG	726	728	ATG	109;109;109	A;T;G	92;89;90	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
